Jane Street’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-26,900
| Closed | -$140K | – | 10901 |
|
|
2024
Q3 | $140K | Sell |
26,900
-13,500
| -33% | -$67.1K | ﹤0.01% | 8846 |
|
|
2024
Q2 | $104K | Buy |
40,400
+5,600
| +16% | +$19.1K | ﹤0.01% | 8714 |
|
|
2024
Q1 | $171K | Buy |
34,800
+11,400
| +49% | +$67.5K | ﹤0.01% | 8270 |
|
|
2023
Q4 | $206K | Sell |
23,400
-41,500
| -64% | -$340K | ﹤0.01% | 8182 |
|
|
2023
Q3 | $744K | Buy |
+64,900
| New | +$1.25M | ﹤0.01% | 5613 |
|
|
2023
Q2 | – | Sell |
-18,300
| Closed | -$589K | – | 9762 |
|
|
2023
Q1 | $589K | Sell |
18,300
-165,800
| -90% | -$5.17M | ﹤0.01% | 6046 |
|
|
2022
Q4 | $3.4M | Buy |
184,100
+76,000
| +70% | +$1.74M | ﹤0.01% | 3027 |
|
|
2022
Q3 | $2.92M | Buy |
108,100
+22,000
| +26% | +$446K | ﹤0.01% | 3504 |
|
|
2022
Q2 | $1.19M | Sell |
86,100
-14,700
| -15% | -$226K | ﹤0.01% | 5158 |
|
|
2022
Q1 | $1.97M | Buy |
100,800
+60,000
| +147% | +$910K | ﹤0.01% | 4791 |
|
|
2021
Q4 | $666K | Buy |
+40,800
| New | +$680K | ﹤0.01% | 6732 |
|
|
2021
Q3 | – | Sell |
-9,600
| Closed | -$285K | – | 10915 |
|
|
2021
Q2 | $285K | Buy |
+9,600
| New | +$277K | ﹤0.01% | 8237 |
|
|
2021
Q1 | – | Sell |
-28,100
| Closed | -$796K | – | 9689 |
|
|
2020
Q4 | $796K | Buy |
+28,100
| New | +$728K | ﹤0.01% | 5031 |
|
Other funds holding RVNC
Jane Street's RVNC Position: Q1 2025 in Review
Jane Street sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 113,150 shares — an estimated $344K sold.
Jane Street first reported a position in RVNC in Q4 2017 and held it in 19 quarters. The position peaked at $8.85M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Jane Street reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Jane Street sold 113,150 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $344K.
- Jane Street first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 19 quarters.
- Jane Street's Revance Therapeutics, Inc. position peaked at $8.85M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.